Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells Four MassArray Systems

NEW YORK, Dec 21 – SEQUENOM has sold MassArray SNP analysis systems to Hitachi, Gemini Genomics, Invitrogen, and AgResearch Limited, a New Zealand agricultural life sciences company, Sequenom announced Thursday.

" With these sales, Sequenom has now announced the placement of more than 20 MassArray systems with a number of the most influential players in the genomics arena in just the first year since the product's commercial launch," Toni Schuh, Sequenom’s president and Chief Executive Officer said in a statement. " This is a clear indication of our global market leadership position for large-scale SNP analysis.“

Sequenom did not disclose the financial terms of the arrangements.

Sequenom has also sold Massarray systems, which cost between $400,000 and $1.1 million depending on the consumables, to a number of public and private research institutions including the Genetics Institute, Genaissance Pharmaceuticals, Integrated DNA technologies, the Sanger Centre, American Home Products, Metabion GmbH and GSF, National Research Center for Environment and Health in Germany and other companies.

Recently, Sequenom announced a partnership with Hitachi, to whom it had sold a previous system, for distribution of its Massarray systems in Japan and for SNP scoring services.

Sequenom also has an existing collaboration with Gemini to identify novel genes.

Invitrogen has said it will use the Massarray as high throughput quality control for its DNA synthesis platforms, and AgResearch will use the sys tem to analyze DNA samples in New Zealand's livestock populations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.